Compare SIMO & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIMO | MYGN |
|---|---|---|
| Founded | 1995 | 1991 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 625.5M |
| IPO Year | 2005 | 1995 |
| Metric | SIMO | MYGN |
|---|---|---|
| Price | $84.62 | $7.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 12 |
| Target Price | ★ $103.13 | $11.82 |
| AVG Volume (30 Days) | 331.7K | ★ 1.0M |
| Earning Date | 02-04-2026 | 11-03-2025 |
| Dividend Yield | ★ 2.34% | N/A |
| EPS Growth | ★ 8.75 | N/A |
| EPS | ★ 2.87 | N/A |
| Revenue | $798,326,000.00 | ★ $825,300,000.00 |
| Revenue This Year | $10.15 | $0.10 |
| Revenue Next Year | $17.72 | $5.28 |
| P/E Ratio | $29.79 | ★ N/A |
| Revenue Growth | N/A | ★ 0.21 |
| 52 Week Low | $37.21 | $3.76 |
| 52 Week High | $106.60 | $15.47 |
| Indicator | SIMO | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 38.86 | 46.44 |
| Support Level | $86.56 | $7.15 |
| Resistance Level | $96.77 | $7.43 |
| Average True Range (ATR) | 3.13 | 0.28 |
| MACD | -0.41 | -0.03 |
| Stochastic Oscillator | 8.64 | 21.20 |
Silicon Motion Technology Corp is engaged in developing NAND flash controllers for SSDs and other solid state storage devices. Its only operating segment is to develop NAND flash controllers and SSDs solutions. The company derives revenue from product categories such as Mobile Storage, Mobile Communications, and others. Silicon's geographical segments are Taiwan, the United States, Korea, China, Singapore, Malaysia, and others. The company products are used in Personal Computing, Smartphone/Tablet/CE, Flash Card/USB Flash Drive, Industrial and Embedded, Automotive, and Enterprise and Data centers.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.